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Background: Decreased expired nitric oxide (eNO) is commonly observed in cystic fibrosis (CF) patients and is usually explained by
dysregulation of NO synthase (NOS) isoforms in respiratory tract epithelium. Later stages of this disease are accompanied by intense airway
infiltration of phagocytes with high NOS activity, abundant levels of the hemoprotein myeloperoxidase (MPO) and significant production of
significant reactive oxygen species.
Methods: This study characterizes the contribution of the high airway levels of MPO to decreased eNO levels in adult CF patients. NO metabolites
(NOx) and MPO levels in fresh sputum of control and adult CF patients were determined and related to measurements of eNO and to in vitro
consumption of NO in CF sputum.
Results: Despite essentially equal levels of NOx in sputum, eNO was 2- to 3-fold lower in CF patients compared to healthy controls. In CF
patients, eNO levels were negatively associated with sputum peroxidase activity. In vivo correlations were confirmed by ex vivo studies of NO
consumption by MPO in CF sputum. Immunodepletion studies confirmed MPO as the major heme peroxidase in CF sputum contributing to the
hydrogen peroxide (H2O2)-dependent consumption of NO.
Conclusions: In CF airways MPO acts as a phagocyte-derived NO oxidase that diminishes NO bioavailability at airway surfaces, possibly
identifying this peroxidase as a potential target for therapeutic intervention.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Myeloperoxidase; Expired nitric oxide; Sputum; Oxidants; Oxidative stress; Neutrophils1. Introduction
Cystic fibrosis (CF) is a progressive autosomal recessive
disease resulting from mutations in the CF transmembrane
conductance regulator gene (CFTR) [1], likely modulated by
variable expressions of several other genes [2]. The physiolog-
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doi:10.1016/j.jcf.2009.10.001tract chloride conductance and increased water resorption,
resulting in increased mucous viscosity and compromised
mucociliary clearance. Due to these abnormalities, patients with
CF are highly susceptible to respiratory tract colonization and
infection, decreased host defenses and overly exuberant
inflammatory responses playing contributory roles [3–5]. The
resulting magnitude of the neutrophilic responses and their
accompanying proteolytic and oxidative processes are believed
to play a major role in the progressive destruction of lung tissues
which characterize CF [6,7].
Consistent with heightened inflammatory/immune processes
associated with most respiratory tract diseases, elevated levels
of expired NO (eNO) are observed in patients with asthma,d by Elsevier B.V. All rights reserved.
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unstable chronic obstructive pulmonary disease [8]. However,
despite intense inflammation and upregulated immune
responses, eNO levels are commonly lower in CF patients
compared to those measured in healthy subjects [9–13]. Indeed,
eNO levels are even lower in patients with more severe CF-
associated lung disease [9]. The mechanisms leading to
decreased levels of eNO in CF are presumably multifactorial
and include respiratory tract epithelial cell decreased NOS
isoform expression [14,15]. The reduction in NO bioavailability
at respiratory tract surfaces may contribute to decreased
antimicrobial host defenses [16,17] and presumably to the
decreased levels of endogenous bronchodilator S-nitrosothiols,
including S-nitroso-glutathione (GSNO), reported in CF
[18,19].
Although secretory lactoperoxidase, H2O2 generating
systems and thiocyanate are believed to also play an important
role in airway antimicrobial systems [20], and may be
defective in CF [5], early bacterial colonization/infection in
the CF respiratory tract and the resulting exuberant phagocytic
responses result in large amounts of neutrophilic myeloper-
oxidase (MPO) in airway secretions [21,22]. In the presence
of H2O2 arising from airway epithelium [23] and neutrophil
NADPH oxidases [24] and the bacteria themselves, it can be
hypothesized that in later stages of the disease, where
infection is presumably most severe, active luminal MPO
may be further compromising the expected inflammation-
based augmentation of airway NO generation. Herein we
provide evidence suggesting that MPO in airway secretions
contributes to decreased eNO levels in adult CF patients with
respiratory tract infections. These results implicate MPO as a
leukocyte-derived airway NO oxidase that limits NO
bioavailability in the inflamed CF lung, thus identifying this
heme peroxidase as a potential molecular target for therapeu-
tic intervention in CF.
2. Methods
2.1. Materials
3,3′,5,5′-Tetramethylbenzidine (TMB) and N,N-dimethyl-
formamide (DMF) were from Sigma-Aldrich (St Louis,
Missouri, USA). DNase (Pulmozyme™) was a gift from
Genentech (South San Franciscso, CA). Mouse monoclonal
antibodies against human MPO were from The Binding Site
(Birmingham, England). Rabbit polyclonal antibodies against
human MPO and purified human MPO were from Calbiochem
(San Diego, California, USA). Goat anti-rabbit IgG antibodies
conjugated to alkaline phosphatase were from ZyMax™ (San
Francisco, California, USA). All other chemicals were of the
highest grade from Fisher Scientific (Houston, Texas, USA) or
Sigma-Aldrich.
2.2. Patients and sputum preparation
The studies were performed with approval from the Office of
Human Research Protection/Institutional Review Board (IRB)of the University of California, Davis. All subjects gave
informed consent. The patients in this study were typical
confirmed adult CF outpatients attending the UC Davis Adult
CF Center clinic. They are characterized by chronic airway
sepsis (infection) and varying degrees of lung impairment. The
patients all had a CF diagnosis based on the CF Foundation
published diagnosis criteria. Patients were aged 19–30, 16% of
which were female. FEV1's ranged from 25 to 80% of
predicted. CFTR genotypes were as typical of our adult CF
patients with ΔF508 prominently represented. No patients were
on steroids (an exclusion criterion). Most cultured positive for
Pseudomonas and were receiving standard CF management,
except that none were actively receiving antibiotics including
tobi or azithromycin at the time of the study. Controls were aged
19–44, 28% of which were female. All were free of respiratory
disease and on no medications. All had FEV1's in the normal
range (N80% of predicted). Spontaneously expectorated sputa
from adult CF patients (N18 years of age) were collected, frozen
immediately and stored at −80 °C until assay. Both controls and
CF patients were asked to extensively void saliva from the
mouth immediately prior to expectorating sputum, thus
minimizing the extent to which saliva contributes to MPO
quantitation. It should be recognized that CF sputum peroxidase
activity is orders of magnitude higher than saliva or control
sputum. Nonetheless, although minimized, we cannot exclude
contributions of small amounts of saliva to the reported
measurements. Subsequently, sputum was thawed and incubat-
ed in an approximately equal volume of 50 mM phosphate
buffer (pH 7.4) containing 0.4 mg/ml DNase (0.2 mg/ml final
concentration). Samples were vortexed for 30 s, incubated at
room temperature for 10 min and centrifuged at 2500g for
20 min at 4 °C [25]. It should be noted that this methodological
approach probably causes lysis of neutrophils with release of
their contained MPO. As both NO and H2O2 are diffusible, NO
oxidation by MPO can occur in both intracellular and
extracellular compartments [26]. Supernatants were removed
for analysis of protein content, heme peroxidase activity and
NO consumption after addition of quantitative amounts of NO.
Expectorated sputa from healthy controls were induced by
inhalation of hypertonic sterile saline (3%) generated by an
Ultraneb 99 ultrasonic nebulizer (De Vilbiss Health Care,
Sommerset, PA) [27]. During 12–15 min of inhalation, subjects
were encouraged to first eliminate saliva, followed by mouth
rinse with water, and then instructed to cough for sputum
collection. The sputum was frozen and processed as described
above. In a second set of CF patients (where expired NO was
measured), sputum was processed by sonication to lyse sputum-
associated leukocytes followed by centrifugation. The resulting
pellet and supernatant were treated with DNase as described
above. The supernatants from both the centrifugation step and
DNase treatment were assayed for heme peroxidase activity and
NO consumption after addition of exogenous NO.
2.3. Expired NO (eNO) measurements
A chemiluminescence-based NO analyzer (Sievers, Boulder,
CO) was used to measure eNO of healthy subjects and CF
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standards. On-line orally-expired NO measurements were
obtained using the restricted breath technique in accordance
with ATS guidelines [28]. Patients performed serial expiratory
vital capacity maneuvers at various expiration rates (40 and
100 ml/s). This method measures lower respiratory tract NO
and minimizes nasal contributions, but does not rigorously
partition NO production between alveolar/small airways and
large airway compartments [29–31], nor take into account
salivary contributions [13,32].
2.4. Heme peroxidase activity measurements
Heme peroxidase activity was determined by measuring the
rate of H2O2-dependent oxidation of TMB. Aliquots of each
sample, containing 5 µg of total protein, were mixed with
sodium acetate buffer (300 mM, pH 5.4, containing 1.2 mM
TMB prepared in DMF) and H2O2 (300 µM) in a total of 200 µl
in microtitre plate wells. The rate of TMB oxidation was
monitored at 630 nm over 2 min on a PowerWavex UV–Vis
plate reader (Bio-Tek Instruments, Inc). Rates are expressed as
ΔOD630/min/mg protein. In some experiments dapsone (1 mM)
was included in the assay buffer.
2.5. NO consumption measurements
Measurements of NO catabolism were made using a NO-
specific electrode (World Precision Instruments) and data
recorded using a Macintosh-based PowerLab data acquisition
software package (ADInstruments, Inc.). Aliquots of the
solubilized sputum samples were incubated in PBS (containing
100 µM DTPA) in a glass chamber equilibrated at 37 °C. When
a stable baseline was achieved, NO (800 nM) was injected as a
bolus from a saturated anaerobic stock NO solution (~1.7 mM).
Once NO had begun to decay at a slow basal rate, hydrogen
peroxide (10 µM) was added. The difference in the rates of NO
decay before and after the addition of H2O2 was used to
determine the MPO-dependent rate of NO consumption in the
soluble sputum samples.
2.6. ELISA for MPO
High-binding Costar brand 96 well plates were coated with
a mouse monoclonal antibody to MPO (The Binding Site,
Inc.; prepared in 50 mM sodium bicarbonate buffer, pH 9.6;
0.7 µg/well) overnight at 4 °C. Wells were then washed five
times with Tris/HCl buffer (50 mM, pH 7.8, containing 150 mM
NaCl and 0.1% Tween-20) and then blocked for 1h at room
temperature with 200 µl 0.1% BSA (prepared in the wash
buffer). MPO standards and processed sputum samples were
diluted in phosphate buffer (20 mM, pH 7.4) containing Tween-
20 (0.1%) and BSA (2 mg/ml). Standards were applied in
triplicate and quantities ranged from 0.16–10 ng/well. Soluble
sputum samples were diluted to yield 1–5 µg of total protein per
well and incubated on the plate for 1h at room temperature.
Wells were then washed (3×), and 100 µl aliquots of a 1:500
dilution of polyclonal rabbit MPO antibody (Calbiochem) wereincubated in the wells for 1h at room temperature. After washing
the wells, 100 µl aliquots of a 1:1000 dilution of ZyMax™
polyclonal, goat anti-rabbit IgG antibody, conjugated to alkaline
phosphatase were incubated in the wells for 1h at room
temperature. The secondary and tertiary antibodies were
prepared in phosphate buffer (20 mM, pH 7.4) containing
NaCl (150 mM) and BSA (2 mg/ml). The wells were washed
extensively and alkaline phosphatase substrate solution added
(100 µl/well of a 1.5 mg/ml 4-nitrophenylphosphate solution
prepared in 1 M diethanolamine, pH 9.8, containing 0.5 mM
MgCl2). The reaction was stopped by the addition of NaOH
(1 M, 50 µl/well, containing 1 mM EDTA) and the plate read at
405 nm.2.7. Western blot analysis of MPO
Aliquots of sputum samples containing low, medium and
high amounts of MPO protein (as determined by ELISA) were
separated by SDS-PAGE on 12% gels under reducing
conditions. Proteins were transferred to nitrocellulose mem-
branes and incubated overnight in PBS containing 0.05%
Tween-20 and 5% non-fat dry milk. Membranes were incubated
with MPO antibody (rabbit polyclonal antibody against human
MPO from Calbiochem) at a dilution of 1:2500. A horseradish
peroxidase-conjugated goat anti-rabbit IgG was used as the
secondary antibody (diluted 1:10,000), followed by detection
using enhanced chemiluminescence.2.8. Immunodepletion of MPO
Sputa from CF patients processed as noted above were
subjected to immunodepletion of MPO using a polyclonal
antibody against human MPO. Briefly, sputum supernatants
were pre-cleared by incubation with protein-G sepharose
(25µl), and the resultant supernatant incubated with 10 µg of
polyclonal MPO antibody for 2 h at 37 °C. Protein-G sepharose
(50µl) was then added and incubation continued for 1h.
Complexes were then removed by centrifugation, and rinsed
three times with PBS. Supernatants were then assessed for MPO
protein by ELISA and NO consumption activity.2.9. Quantitation of NO metabolites (NOx) in sputum
Nitrite (NO2
−) and nitrate (NO3
−) in soluble supernatants of
DNase-treated CF sputum and induced sputum from healthy
subjects were detected as NO following reduction with
vanadium III under acidic conditions at 95 °C, on an Antek
7020 Chemiluminescence NO detector (Antek Instruments,
Houston, TX) as previously described [22].2.10. Statistics
All data are expressed as the average±SD. Details of
individual statistical tests are noted in the figure legends.
87A.L.P. Chapman et al. / Journal of Cystic Fibrosis 9 (2010) 84–923. Results
3.1. Heme peroxidase activity and eNO
Orally-expired NO (eNO) was quantified in adult CF
patients and the levels compared to the heme peroxidase
activity in their respective sputum samples. There was no
significant relationship between eNO levels and MPO activity
in the supernatant of sputum solubilized by centrifugation
alone (data not shown). However, when the pellet remaining
after centrifugation was subjected to DNase treatment (which
liberates extensive quantities of MPO from the insoluble
mucus), low levels of expired NO correlated with high levels
of heme peroxidase activity in the solubilized sputum of CF
patients (Fig. 1A,C). Compared to normal controls, CF
patients had 2- to 3-fold lower eNO levels. As shown for
two expiratory flow rates (40 and 100 ml/s), a dramatically
low eNO to heme peroxidase ratio characterizes adult CF
patients. These data support our hypothesis that the previously
described NO oxidase activity of MPO [26,33] may contribute
to decreased eNO in CF patients with significant respiratory
tract infections.Fig. 1. High peroxidase activity is associated with decreased eNO in CF patients. Sh
against sputum heme peroxidase activity (A, C). Symbols denoted with an asterisk (
subjects (n=7). Data are also represented as the ratio of eNO to heme peroxidase acti
Whitney test revealed that there was a statistically significant difference in the ratio
specifically, the ratio of eNO (at both 40 ml/s and 100 ml/s) to peroxidase activity wa3.2. NO metabolites in sputum
As shown in Fig. 2, and despite the rather large spread of
data, the levels of total NO metabolites (NOx) were not
significantly different between normal controls (112±25 µM)
and adult CF patients (132±30 µM). This suggests that the
decreased eNO observed in CF patients with airway infections,
compared to controls, is not due to an overall compromised NO
synthesis within the respiratory tract. In contrast, these results
suggest that NO catabolism within the airway prior to
exhalation in the gas phase is responsible for the decline in
eNO in CF patients with airway infections. When NO is
oxidized by MPO, NO2
− is generated [26,33]. Continued
oxidation of NO2
− results in the formation of NO3
− by MPO
and other oxidative processes. Thus, the relative quantities of
NO, NO2
− and NO3
− provide mechanistic insight into potential
routes of NOmetabolism in the CF lung. In contrast to total NOx
levels which did not differ between controls and CF patients, the
ratio of NO2
− to NO3
− was lower in CF sputum (0.26±0.1)
compared to that observed in induced sputum from healthy
subjects (0.46±0.1). This suggests that more NO3
− was
generated relative to NO2
− in CF compared to control subjects,own are eNO levels measured at two different expiration flow rates and plotted
*) indicate CF patients (n=6), those without an asterisk indicate normal control
vity for normal controls and CF patients (B, D). A two-sided Wilcoxon–Mann–
of eNO (40 ml/s) and eNO (100 ml/s) to peroxidase activity (p=0.001). More
s statistically significantly higher in the normal group compared to the CF group.
Fig. 2. Expectorated sputum NOx (NO2
−+NO3
−) levels are not different between
normal and CF patients. A scatter plot is shown for 6 normal controls and 12 CF
patients. The average±SEM for controls and CF patients was 133±30 µM and
132±30 µM, respectively. A two-sided Wilcoxon–Mann–Whitney test
revealed that there was no statistically significant difference in sputum NOx
between the two groups (p=1.0).
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airway [7].
3.3. Relationship between peroxidase activity, MPO protein
and NO consumption
Heme peroxidase activity was measured in the DNase-
treated CF sputum by determining the rate of TMB oxidation.
The rate of TMB oxidation (which reflects heme peroxidase
activity) ranged from ~1 to 23 OD650/min/mg protein in CF
sputum (n=16). An association was observed between the level
of sputum heme peroxidase activity and H2O2-dependent NO
consumption rates (Fig. 3), as quantified with an NO-specific
electrode. This trend, however, did not reach statistical
significance (p=0.163). Of note, the NO oxidizing activity of
CF sputum (and purified MPO) remains quantitatively andFig. 3. Relationship between ex vivo NO consumption rates and sputum
peroxidase activity in CF patients. Data represent sputum from 16 individual
adult CF patients. Whereas there was a trend toward a direct relationship, the
two-sided p-value using Spearman's rank correlation coefficient (ρ=0.366;
ASE=0.222) to assess the association between NO consumption rate and
peroxidase activity was 0.163, indicating no statistically significant association.kinetically essentially the same over pH values between 6.0 and
8.0 (data not shown).
To determine whether the peroxidase responsible for TMB
oxidation and NO consumption was MPO, the amount of MPO
protein in the samples was determined by aMPO-specific ELISA.
Higher rates of H2O2-dependent NO consumption were observed
in sputum specimens containing larger quantities of MPO protein
(Fig. 4A). This association did reach statistical significance
(p=0.004). In addition, sputum samples shown to contain low,
medium and high amounts of MPO determined by ELISA were
separated by SDS-PAGE and a western blot was probed for the
MPO heavy chain. The intensity of staining on the blot agreed
qualitatively with the results obtained by ELISA (Fig. 4B).
Lactoperoxidase (LPO) has been identified as a major heme
peroxidase in normal disease-free respiratory tract secretions
[34] and is also able to consume NO [33] and be modulated
itself by NO [35]. While our data suggest that the peroxidase
responsible for NO consumption in CF sputum is MPO, it is
possible that LPO may contribute. To define the contribution of
LPO, peroxidase activity and NO consumption measurements
were performed in the presence of 4,4′-diaminodiphenylsulfone
(dapsone, 1 mM), as lactoperoxidase is more sensitive to
inhibition by dapsone than MPO [36]. Dapsone did not inhibit
peroxidase activity nor did it significantly alter NO consump-
tion in CF sputum samples (data not shown), yet the peroxidase
activity and NO consumption activity of purified LPO are
inhibited by dapsone. These data further support a role for
neutrophil-derived MPO as the predominant peroxidase at
respiratory tract surfaces in CF patients.Fig. 4. Ex vivo NO consumption rates are directly proportional to sputum MPO
protein levels in CF patients. MPO protein levels in CF sputum, determined by
ELISA (A), were generally confirmed by Western blotting (B). Low, medium,
and high in panel B refer to representative CF patients who had MPO levels
determined by ELISA in the lowest third, the middle third, and the highest third,
respectively (two independent patients per category). The two-sided p-value
using Spearman's rank correlation coefficient (ρ=0.697; ASE=0.164) to assess
the association between NO consumption rate and MPO protein was 0.004,
which indicates that there was a statistically significant association between NO
consumption rate and MPO protein.
Fig. 5. MPO is the major heme peroxidase in CF sputum responsible for NO
consumption. Immunodepletion of MPO from sputum of 4 CF patients
decreases ex vivo NO consumption rates (open bars) and MPO protein as
determined by ELISA (filled bars). Values are represented as a percentage of
control values (set at 100%) in identical specimens treated and processed
identically, but without addition of the anti-MPO antibody. Each bar indicates
the average of two independent determinations. The p-value of the two-sided
Wilcoxon signed-rank test was 0.125, which reveals that there was no
statistically significant difference between MPO protein and NO consumption.
Fig. 6. Bidirectional modulation of peroxidase-dependent NO consumption in CF spu
indicate additions of H2O2 (10 µM). Shown are peroxidase/H2O2-dependent NO consum
(B). Tyrosine increases peroxidase/H2O2-dependent NO consumption in a concentr
consumption rates in CF sputum (D) and CF sputum supplemented with 500 µM Tr
concentration-dependent manner (F). Values in C and F represent the average±SD.
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To further define the role of MPO as a catalyst of NO
catabolism in CF sputum, experiments were performed using
specific antibodies to deplete MPO. Immunodepletion of MPO
resulted in substantially reduced NO consumption rates in CF
sputum (Fig. 5A), that were paralleled by a decrease in MPO
protein (Fig. 5B). Collectively, these results provide strong
evidence supporting a role for MPO as the major heme
peroxidase responsible for catalyzing H2O2-dependent NO
consumption in CF sputum. The data may illuminate a
mechanism contributing to decreased exhaled NO in adult CF
patients with on-going progressive respiratory tract infections.
3.5. Bidirectional modulation of peroxidase/H2O2-dependent
NO consumption in CF sputum
MPO can act as a NO oxidase by generating substrate
radicals (such as tyrosyl radicals) that oxidize NO [26,37].
Thus, we determined the effect added tyrosine would have on
NO consumption in CF sputum. Real-time traces indicating NO
oxidation are shown for the reaction with CF sputum in the
absence and presence of tyrosine (Fig. 6A,B) or Trolox
(Fig. 6D,E). Addition of tyrosine to sputum increased H2O2-
dependent NO consumption in a concentration-dependenttum. Traces indicating real-time NO levels are shown in A, B, D and E. Arrows
ption rates in CF sputum (A) or CF sputum supplemented with 500µM L-tyrosine
ation-dependent manner (C). Also shown are peroxidase/H2O2-dependent NO
olox (E). Trolox decreases peroxidase/H2O2-dependent consumption of NO in a
Fig. 7. Schematic illustrating potential pathways for modulating MPO-
dependent NO metabolism in airway secretions of CF patients. Second order
rate constants are given with units of M−1 s−1 for reactions. Tyrosine enhances
MPO-dependent consumption of NO, whereas Trolox inhibits MPO-dependent
consumption of NO.
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consumption in a concentration-dependent manner (Fig. 6F).
These data provide a means of achieving either enhanced or
diminished NO oxidation in CF respiratory tract secretions as
measured in expectorated sputum.
4. Discussion
CF airways are infiltrated by extraordinarily high numbers of
neutrophils resulting in the release of high concentrations of
MPO into the respiratory tract fluids [21,22]. The levels of
expired NO (eNO) are consistently low in CF patients [9–12]
compared to patients with other inflammatory lung diseases or
healthy subjects. The complex pathophysiology of this disease
has made it difficult to characterize all of the mechanisms
contributing to this finding. Evidence is conflicting, with levels
of NO metabolites measured in some studies being elevated
[12,38] while other studies have shown variably reduced
expression of inducible NO synthase [14,39]. Importantly,
pharmacologic manipulation of NO in patients with CF has
been proposed as a therapeutic approach to modulating disease
progression [19,40,41]. In the present study, we have shown
that the levels of expired NO negatively correlate with MPO
activity in CF sputum, supported by in vitro studies showing
that CF sputum with high levels of MPO oxidize NO at high
rates.
MPO is an NO oxidase which utilizes substrate radicals to
oxidize NO to NO2
− [26]. Thus, a plausible explanation for the
lowered expired NO in CF with intense respiratory tract
inflammation is the catalytic consumption of NO by MPO. We
have shown that DNase-treated sputum consumes NO and that
the sputum with the highest rates of NO consumption also had
the highest levels of MPO (Fig. 4). NO oxidase activity is not
restricted to MPO. Lactoperoxidase and eosinophil peroxidase
can also consume NO [33]. While eosinophils are prevalent
during hypersensitive responses such as allergen induced
asthma [42], their numbers are not elevated in CF [43,44].
While it is clear that most inflammatory lung diseases are
associated with increased expired NO and increased heme
peroxidase activity, it should be pointed out that the levels of
heme peroxidases in asthma is orders of magnitude lower as
compared to levels reported in CF. It seems possible that
expired NO levels could be even higher in asthma if the heme
peroxidases (ie. eosinophil peroxidase) were not expressed by
the infiltrating phagocytic cells. Respiratory tract lactoperox-
idase is involved in respiratory tract antimicrobial activities
[23]. However, in the present studies selective inhibition of
lactoperoxidase by dapsone did not inhibit the peroxidase-
dependent consumption of NO or the oxidation of TMB. Using
an ELISA method for MPO protein and immunoblotting protein
in the samples with an antibody to the heavy chain of MPO, we
have demonstrated that the peroxidase consuming NO in CF
sputum is highly associated with MPO. Lastly, immunodeple-
tion studies have revealed that MPO is the primary NO
consuming heme peroxidase in CF sputum.
The bidirectional modulation of MPO-dependent NO
consumption by Trolox or tyrosine offers a novel theoreticalconstruct for altering NO bioavailability in CF airways (Fig. 7).
For example, administration of Trolox into the CF airway would
increase bioavailable NO and increase its pleotropic airway
effects [45]. In contrast, administration of tyrosine would
accelerate the oxidative consumption of NO and further
decrease airway NO bioavailability. Interestingly, ascorbic
acid (vitamin C), a reductant that has been suggested for airway
administration as an ‘antioxidant’ and a possible CFTR
activator [46], would act like tyrosine and accelerate MPO-
dependent consumption of NO [26]. Of relevance, recent
studies have suggested that exogenous NO2
− at the mildly acidic
pH of airway secretions can be transformed into NO that could
potentially facilitate the killing of mucoid bacteria in anaerobic
biofilms [40]. Not only would this provide for increased
bioavailable NO, therapeutic concentrations of NO2
− (~15 mM)
could also serve to inhibit MPO and its NO consuming activity
[47].
Some limitations of the current methodology should be
mentioned. In order to mimic H2O2 generation systems by
phagocytes, bacteria and/or respiratory tract cells, small
amounts of H2O2 (10 µM) were added to activate MPO which
may or may not reflect the scenario in the infected and inflamed
CF lung. Although our data suggest that MPO is the primary
catalyst of H2O2 and NO consumption, we cannot exclude the
contribution of other heme peroxidases or redox-active metals
within CF sputum [48]. Because of the wide variation of sputum
NOx values and great variability of sputum volume production
by individual CF patients, no attempts were made to present
stoichiometric correlations among eNO, sputum MPO and
sputum NOx (as would be ideal). Finally, the present data make
no attempt to quantitate the number of other potential
mechanisms for NO oxidative metabolism in the CF airway
as might be expected to occur via reactions with other reactive
oxygen species (ie. superoxide) or even the colonized bacteria
themselves.
91A.L.P. Chapman et al. / Journal of Cystic Fibrosis 9 (2010) 84–92In conclusion, the consumption of NO by MPO in CF airways
may contribute, at least in part, to the reduction in expired NO
measured in this patient population. Pharmacologic inhibition of
MPOmayprovide a useful therapeutic approach inCFbydecreasing
oxidant burden and preserving the functions of NO as a
bronchodilator, bacteriostatic agent, and anti-inflammatorymediator.Acknowledgements
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